UK drug regulator approves Alzheimer’s drug but government likely won’t pay for it
LONDON — Britain’s drug regulator authorized the Alzheimer’s drug Leqembi on Thursday, saying it’s the first medicine to show some impact in slowing the progression of the neurodegenerative disease. But the U.K. government likely won’t be paying for it after an independent agency separately issued draft guidance concluding that the benefits of Leqembi “cannot be … Read more
